| 词条 | Ibotenic acid |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 476996586 | ImageFile1 = ibotenic_acid2.png | ImageSize1 = 150px | ImageFile2 = Ibotenic_acid_3D_structure.png | ImageSize2 = 150px | IUPACName = (S)-2-Amino-2-(3-hydroxyisoxazol-5-yl)acetic acid | OtherNames = Ibotenic acid |Section1={{Chembox Identifiers | Abbreviations = | InChI = 1/C5H6N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h1,4H,6H2,(H,7,8)(H,9,10) | InChIKey = IRJCBFDCFXCWGO-UHFFFAOYAQ | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 284895 | ChEMBL2_Ref = {{ebicite|correct|EBI}} | ChEMBL2 = 30285 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C5H6N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h1,4H,6H2,(H,7,8)(H,9,10) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = IRJCBFDCFXCWGO-UHFFFAOYSA-N | CASNo_Ref = {{cascite|changed|??}} | CASNo = 2552-55-8 | EINECS = | PubChem = 1233 | IUPHAR_ligand = 1371 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 1196 | SMILES = O=C1/C=C(\\ON1)C(C(=O)O)N | RTECS = | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = |Section2={{Chembox Properties | C=5|H=6|N=2|O=4 | Appearance = | Density = | MeltingPt = 151-152 °C (anhydrous) 144-146 °C (monohydrate) | BoilingPt = | Solubility = H2O: 1 mg/mL 0.1 M NaOH: 10.7 mg/mL 0.1 M HCl: 4.7 mg/mL | pKa = | pKb = | IsoelectricPt = | SpecRotation = | RefractIndex = | Viscosity = | Dipole = |Section5={{Chembox Pharmacology | ATCCode = | Bioavail = | Metabolism = | HalfLife = | Excretion = | PregCat = | AdminRoutes = |Section7={{Chembox Hazards | EUClass = | MainHazards = | NFPA-H = | NFPA-F = | NFPA-R = | NFPA-O = | RPhrases = | SPhrases = | RSPhrases = | FlashPt = | AutoignitionPt = | ExploLimits = | PEL = |Section9={{Chembox Related | OtherAnions = | OtherCations = | OtherFunctn = | Function = | OtherCpds = }}Ibotenic acid or (S)-2-amino-2-(3-hydroxyisoxazol-5-yl)acetic acid, also referred to as ibotenate, is a chemical compound and psychoactive drug which occurs naturally in Amanita muscaria and related species of mushrooms typically found in the temperate and boreal regions of the northern hemisphere. It is a conformationally-restricted analogue of the neurotransmitter glutamate, and due to its structural similarity to this neurotransmitter, acts as a non-selective glutamate receptor agonist.[1] Because of this, ibotenic acid can be a powerful neurotoxin, and is employed as a "brain-lesioning agent" through cranial injections in scientific research.[2][3] PharmacologyIbotenic acid acts as a potent agonist of the NMDA and group I (mGluR1 and mGluR5) and II (mGluR2 and mGluR3) metabotropic glutamate receptors.[1][4] It is inactive at group III mGluRs.[5] Ibotenic acid also acts as a weak agonist of the AMPA and kainate receptors.[1][4] In addition, due to in vivo decarboxylation into muscimol, it acts indirectly as a potent GABAA and GABAA-ρ receptor agonist.[4] Unlike muscimol, the principal psychoactive constituent of Amanita muscaria that is understood to cause sedation and delirium, ibotenic acid's psychoactive effects are not known independent of its serving as a prodrug to muscimol, however it may be speculated that it would act as a stimulant.[6][7] {{clear}}Biological propertiesMechanism of actionIbotenic acid is an agonist of glutamate receptors, specifically at both the N-methyl-D-aspartate, or NMDA and trans-ACPD receptor sites in a multiple of systems in the central nervous system. Ibotenic neurotoxicity can be enhanced by glycine and blocked by dizocilpine. Dizocilpine acts as an uncompetitive antagonist at NMDA receptors.[8] Ibotenic acid toxicity comes from activation of the NMDA receptors. NMDA receptors are related to synaptic plasticity and work with metabotropic glutamate receptors to establish long term potentiation or LTP. The process of long term potentiation is believed to be related to the acquisition of information. The NMDA receptor functions properly by allowing Ca2+ ions to pass through after activation at the receptor site. The binding of ibotenic acid allows excess Ca2+ into the system which results in neuronal cell death. Ca2+ also activates CaM-KII or Ca2+/Calmodulin Kinase which phosphorylates multiple enzymes. The activated enzymes then begin producing reactive oxygen species which damages surrounding tissue. The excess Ca2+ results in the enhancement of the mitochondrial electron transport system which will further increase the number of reactive oxygen species.[9] Biological effectsIbotenic acid typically affects NMDA and trans-ACPD receptors in the central nervous system.[8] Due to their targeting of these systems the symptoms associated with Ibotenic acid poisoning are often related to perception and control. Most of ingested ibotenic acid is probably decarboxylated into muscimol so the effects of ingesting ibotenic acid are similar to muscimol's effects.[10] Symptoms associated with ibotenic acid are usually onset within 30–60 minutes and include a range of nervous system effects. The most common symptoms include, nausea, vomiting, and drowsiness. However, after the first hour symptoms begin to include confusion, euphoria, visual and auditory distortions, sensations of floating, and retrograde amnesia.[16] Symptoms are slightly different for children, typically beginning after 30–180 minutes. Dominant symptoms in children include ataxia, obtundation, and lethargy. Seizures are occasionally reported, however, more commonly with children.[11] TreatmentTreatment of ibotenic acid poisoning is limited and varies as the toxic dose of the compound varies from person to person. Patients admitted to the hospital for ibotenic acid poisoning are typically given charcoal in order to stop the absorption of the compound and prevent further intoxication. Upon receiving charcoal treatment the patient’s vital signs are monitored and toxicity usually lasts between 6 and 8 hours; however, some symptoms may take up to a few days to subside. Occasionally, to reduce the discomfort associated with symptoms, benzodiazepines will be administered to control panic attacks and hallucinations. Special attention should be given to monitoring breathing, airway control, and circulation. If treatment occurs within the first hour of ingestion gastric lavage may be effective. If vomiting becomes too intense intravenous fluids are administered, psychiatric care may also be provided. In rare cases anticholinergic drugs, such as atropine, may be needed.[12] Use in researchIbotenic acid used for the lesioning of rat's brains is kept frozen in a phosphate-buffered saline solution at a pH of 7.4, and can be kept for up to a year with no loss in toxicity. Injection of .05-.1 microliters of Ibotenic acid into the hippocampus at a rate of .1 microliter/min resulted in semi-selective lesioning. Hippocampal lesioning led to a considerable loss of cells in pyramidal cells (CA1-CA3) as well as granule cells in the dentate gyrus. Ibotenic acid lesioning also causes some damage to axons along the perforant pathway. Typically when lesioning is done with other chemicals the subject can not relearn a task. However, due to Ibotenic acid's reactivity with glutamate receptors such as the NMDA receptor, Ibotenic acid lesioning does allow the subject to relearn tasks. Ibotenic acid lesioning is thus preferred in studies where re-learning a task after lesioning is essential. Compared to other lesioning agents, Ibotenic acid is one of the most site-specific; however, less-damaging alternatives are presently sought.[13] See also
References1. ^1 2 {{cite book|author1=Tommy Liljefors|author2=Povl Krogsgaard-Larsen|author3=Ulf Madsen|title=Textbook of Drug Design and Discovery, Third Edition|url=https://books.google.com/books?id=EL-UI6t8omQC&pg=PA263|date=25 July 2002|publisher=CRC Press|isbn=978-0-415-28288-8|pages=263–}} {{Poisonous Amanitas}}{{Toxins}}{{Neurotoxins}}{{GABA receptor modulators}}{{GABA metabolism and transport modulators}}{{Glutamate receptor modulators}}{{Authority control}}2. ^{{Cite journal | last1 = Becker | first1 = A | last2 = Grecksch | first2 = G | last3 = Bernstein | first3 = HG | last4 = Höllt | first4 = V | last5 = Bogerts | first5 = B | title = Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis | journal = Psychopharmacology | volume = 144 | issue = 4 | pages = 333–8 | year = 1999 | pmid = 10435405| doi=10.1007/s002130051015}} 3. ^{{Cite journal | last1 = Isacson | first1 = O | last2 = Brundin | first2 = P | last3 = Kelly | first3 = PA | last4 = Gage | first4 = FH | last5 = Björklund | first5 = A | title = Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum | journal = Nature | volume = 311 | issue = 5985 | pages = 458–60 | year = 1984 | pmid = 6482962|bibcode = 1984Natur.311..458I |doi = 10.1038/311458a0 }} 4. ^1 2 {{cite book|author=Wantanabe|title=Pharmacological Research on Traditional Herbal Medicines|url=https://books.google.com/books?id=UExUOKw3EwYC&pg=PA107|date=23 July 1999|publisher=CRC Press|isbn=978-90-5702-054-4|pages=107–}} 5. ^{{cite journal | vauthors = Hermit MB, Greenwood JR, Nielsen B, Bunch L, Jørgensen CG, Vestergaard HT, Stensbøl TB, Sanchez C, Krogsgaard-Larsen P, Madsen U, Bräuner-Osborne H | title = Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors | journal = Eur. J. Pharmacol. | volume = 486 | issue = 3 | pages = 241–50 | year = 2004 | pmid = 14985045 | doi = 10.1016/j.ejphar.2003.12.033 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014299903028395}} 6. ^Chilton 1975; Theobald et al. 1968 7. ^Chilton 1975; Ott 1976a 8. ^1 {{cite journal|last1=Zinkand|first1=William|last2=Moore|first2=W.|last3=Thompson|first3=Carolann|last4=Salama|first4=Andre|last5=Patel|first5=Jitendra|title=Ibotenic acid mediates neurotoxicity and phosphoinositide hydrolysis by independent receptor mechanisms|journal=Molecular and Chemical Neuropathology|date=February 1992|volume=16|issue=1–2|pages=1–10|doi=10.1007/bf03159956|pmid=1325800}} 9. ^{{cite web|last1=Sureda|first1=F.|title=Excitotoxicity and the NMDA receptor|url=http://www.eurosiva.org/archive/vienna/abstracts/speakers/sureda.htm|website=eurosiva|accessdate=30 April 2015}} 10. ^{{Cite journal|last=Michelot|first=Didier|last2=Melendez-Howell|first2=Leda Maria|date=2003|title=Amanita muscaria: chemistry, biology, toxicology, and ethnomycology|url=http://www.davidmoore.org.uk/21st_Century_Guidebook_to_Fungi_PLATINUM/REPRINT_collection/Michelot_etal_A.muscaria_chemistry_biology_toxicology.pdf|journal=Mycological Research|volume=107|issue=2|pages=131–146|doi=10.1017/s0953756203007305|pmid=12747324|via=}} 11. ^1 {{cite web|last1=Duffy|first1=Thomas|title=Symptoms of ibotenic/muscimol poisoning (isoxazol poisoning)|url=http://www.mykoweb.com/TFWNA/P-28.html|website=Toxic Fungi of Western North America|publisher=MykoWeb|accessdate=30 April 2015}} 12. ^{{cite web|last1=Rolston-Cregler|first1=Louis|title=Hallucinogenic Mushroom Toxicity|url=http://emedicine.medscape.com/article/817848-overview|website=MedScape|accessdate=30 April 2015}} 13. ^{{cite journal|last1=Jarrard|first1=Leonard|title=On the use of ibotenic acid to lesion selectively different components of the hippocampal formation|journal=Journal of Neuroscience Methods|date=2 February 1989|volume=29|issue=3|pages=251–259|url=http://ac.els-cdn.com/0165027089901490/1-s2.0-0165027089901490-main.pdf?_tid=61f76582-ee0d-11e4-8f57-00000aacb35e&acdnat=1430270377_cd4931c1ae8fc4422ae0b404044cb31d|accessdate=29 April 2015|doi=10.1016/0165-0270(89)90149-0}} 17 : Toxic amino acids|Psychedelic drugs|Neurotoxins|Mycotoxins found in Basidiomycota|Prodrugs|Isoxazoles|Hydroxy acids|AMPA receptor agonists|GABAA receptor agonists|GABAA-rho receptor agonists|Kainate receptor agonists|MGlu1 receptor agonists|MGlu2 receptor agonists|MGlu3 receptor agonists|MGlu5 receptor agonists|NMDA receptor agonists|Excitotoxins |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。